Metaiodobenzylguanidine and Somatostatin in Oncology: Role in the Management of Neural Crest Tumours

Overview

Journal Eur J Nucl Med

Specialty Nuclear Medicine

Date 1994 Jun 1

PMID 7915987

Citations 37

Authors

C A Hoefnagel

Affiliations

Soon will be listed here.

Abstract

Two recently developed radiopharmaceuticals, iodine-131 metaiodobenzylguanidine (MIBG) and indium-111 pentetreotide, are currently being used for the diagnosis and therapy of neural crest tumours by interaction with the characteristic features of these tumours, such as an active uptake-1 mechanism at the cell membrane and the presence of vesicles or neurosecretory granules in the cytoplasm and of specific receptors at the cell membrane. This review focuses on the role of MIBG and somatostatin analogues in the management of neural crest tumours. A number of aspects of both tracers are compared and the cumulative results are reviewed. Other uses of these radiopharmaceuticals are mentioned. It is concluded that both 111In-pentetreotide and 123I/131I-MIBG are sensitive indicators of neural crest tumours, and have a complementary role. Unlike MIBG, 111In-pentetreotide is not specific for neural crest tumours, as scintigraphy is also positive in many other tumours, granulomas and autoimmune diseases. 131I-MIBG is effective in the therapy of several neural crest tumours; the biodistribution of 111In-pentetreotide at present does not allow radionuclide therapy using a beta-emitting label. However, as an indicator of somatostatin receptors, 111In-pentetreotide scintigraphy may be a predictor of response to palliative treatment with unlabelled octreotide. Recommendations for the use of these procedures are given.

Citing Articles

Ga-DOTATATE PET/CT Compared with I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors.

Shahrokhi P, Emami-Ardekani A, Harsini S, Eftekhari M, Fard-Esfahani A, Fallahi B Asia Ocean J Nucl Med Biol. 2020; 8(1):8-17.

PMID: 32064278 PMC: 6994775. DOI: 10.22038/aojnmb.2019.41343.1280.

Mid-Gut Carcinoid Tumour Presenting as Suspected Orbital Metastasis.

Hafiz A, Ali S, Sidahmed S, Al-Hassan A, El-Naggar N Sultan Qaboos Univ Med J. 2019; 19(3):e253-e256.

PMID: 31728225 PMC: 6839673. DOI: 10.18295/squmj.2019.19.03.013.

Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease.

Kroiss A Wien Med Wochenschr. 2018; 169(1-2):25-32.

PMID: 30182289 DOI: 10.1007/s10354-018-0658-7.

Fluorine-18-fluorodihydroxyphenylalanine Positron-emission Tomography Scans of Neuroendocrine Tumors (Carcinoids and Pheochromocytomas).

Zanzi I, Studentsova Y, Bjelke D, Warner R, Babchyck B, Chaly T J Clin Imaging Sci. 2017; 7:20.

PMID: 28584687 PMC: 5450503. DOI: 10.4103/jcis.JCIS_107_16.

Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tract and the pancreas.

Gut P, Fischbach J, Kaminski G, Ruchala M Contemp Oncol (Pozn). 2013; 16(5):371-5.

PMID: 23788913 PMC: 3687448. DOI: 10.5114/wo.2012.31764.

References

BEIERWALTES W . Update on basic research and clinical experience with metaiodobenzylguanidine. Med Pediatr Oncol. 1987; 15(4):163-9. DOI: 10.1002/mpo.2950150405. View

Catt K, Harwood J, Aguilera G, Dufau M . Hormonal regulation of peptide receptors and target cell responses. Nature. 1979; 280(5718):109-16. DOI: 10.1038/280109a0. View

Itoh H, Sugie K, Toyooka S, Kawase M, MUKAINO S, Hazama F . Detection of metastatic medullary thyroid cancer with 131I-MIBG scans in Sipple's syndrome. Eur J Nucl Med. 1986; 11(12):502-4. DOI: 10.1007/BF00252798. View

Lumbroso J, Guermazi F, Hartmann O, Coornaert S, Rabarison Y, Lemerle J . [Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of neuroblastoma: analysis of 115 cases]. Bull Cancer. 1988; 75(1):97-106. View

Reubi J, Maurer R . Autoradiographic mapping of somatostatin receptors in the rat central nervous system and pituitary. Neuroscience. 1985; 15(4):1183-93. DOI: 10.1016/0306-4522(85)90261-1. View

Krenning E, Kwekkeboom D, Bakker W, Breeman W, Kooij P, Oei H . Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993; 20(8):716-31. DOI: 10.1007/BF00181765. View

Krenning E, Bakker W, Kooij P, Breeman W, Oei H, de Jong M . Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992; 33(5):652-8. View

van Gils A, van der Mey A, Hoogma R, Falke T, MOOLENAAR A, Pauwels E . Iodine-123-metaiodobenzylguanidine scintigraphy in patients with chemodectomas of the head and neck region. J Nucl Med. 1990; 31(7):1147-55. View

Jodrell D, Irvine A, McCready V, Woodcraft E, Smith I . The use of 131I-MIBG in the imaging of metastatic carcinoid tumours. Br J Cancer. 1988; 58(5):663-4. PMC: 2246815. DOI: 10.1038/bjc.1988.281. View

10.

. The role of [131I]Metaiodobenzylguanidine in the treatment of neural crest tumors. Proceedings of an international workshop. Rome, Italy, September 6-7, 1991. J Nucl Biol Med (1991). 1991; 35(4):177-363. View

11.

Khafagi F, Shapiro B, Fig L, Mallette S, Sisson J . Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med. 1989; 30(4):481-9. View

12.

Kokoschka E, Ulrich W, Sinzinger H . 131I-metaiodobenzylguanidine (mIBG) for bronchial oat cell cancer and melanoma detection?. Eur J Nucl Med. 1989; 15(9):629-31. DOI: 10.1007/BF00256943. View

13.

Valdes Olmos R, Hoefnagel C, VAN DER SCHOOT J . Nuclear medicine in the monitoring of organ function and the detection of injury related to cancer therapy. Eur J Nucl Med. 1993; 20(6):515-46. DOI: 10.1007/BF00175165. View

14.

Trautmann M, Neuhaus C, Lenze H, Benning R, Benning M, Dennler H . The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors. Horm Metab Res Suppl. 1993; 27:24-7. View

15.

von Moll L, McEwan A, Shapiro B, Sisson J, Gross M, Lloyd R . Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Med. 1987; 28(6):979-88. View

16.

Anderson B, BEIERWALTES W, Harrison T, Ansari A, Buswink A, Ice R . Labeled dopamine concentration in pheochromocytomas. J Nucl Med. 1973; 14(11):781-4. View

17.

BAUER W, Briner U, DOEPFNER W, Haller R, HUGUENIN R, Marbach P . SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982; 31(11):1133-40. DOI: 10.1016/0024-3205(82)90087-x. View

18.

Swensen S, Brown M, Sheps S, Sizemore G, Gharib H, Grant C . Use of 131I-MIBG scintigraphy in the evaluation of suspected pheochromocytoma. Mayo Clin Proc. 1985; 60(5):299-304. DOI: 10.1016/s0025-6196(12)60536-9. View

19.

Feldman J, Blinder R, Lucas K, Coleman R . Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors. J Nucl Med. 1986; 27(11):1691-6. View

20.

Baulieu J, Guilloteau D, Delisle M, Perdrisot R, Gardet P, Delepine N . Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study. Cancer. 1987; 60(9):2189-94. DOI: 10.1002/1097-0142(19871101)60:9<2189::aid-cncr2820600913>3.0.co;2-c. View